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Resumen
Introducción: Muchas notificaciones en la bibliografía
han puesto de manifiesto las características particulares
del Lactobacillus paracasei, subespecie paracasei F19; sin
embargo, la revisión crítica de los principales resultados
clínicos aún no se ha realizado.
Objetivos: Esta revisión resume los artículos más rele-
vantes, en términos de beneficios clínicos, sobre adminis-
tración del  Lactobacillus paracasei, subespecie paracasei
F19, revisando su historia y recalcando nuevas perspecti-
vas interesantes sobre su uso en la práctica clínica. 
Métodos: realizamos una búsqueda en Pubmed/Med-
line usado los términos “Lactobacillus paracasei subsp
paracasei F19”. Se incluyeron todos los artículos experi-
mentales que empleasen el Lactobacillus paracasei, subes-
pecie paracasei F19.
Resultados y discusión: La estabilidad genética de F19,
su característica clínica más relevante, hace que su admi-
nistración sea fiable y eficaz en personas inmunosuprimi-
das. Las concentraciones adecuadas de esta cepa apoyan
una estrategia de dosis/efecto que varía entre la activa-
ción de los macrófagos del hospedador hasta un control
del sobrecrecimiento de bacterias patógenas, así como
una adecuada interacción  con las terminaciones nervio-
sas intestinales. Además, los resultados preliminares de
nuestro laboratorio apoyan la formulación encapsulada
de Lactobacillus F19 con AH liofilizada en pacientes con
EII debido a una mayor adherencia de la cepa a la mucosa
y un posible favorecimiento de la proliferación y manteni-
miento de la cepa.
Conclusiones: Se necesitan experimentos adicionales
para paliar el déficit de información acerca de esta nueva
formulación para el tratamiento de la EII.
(Nutr Hosp. 2013;28:1842-1850)
DOI: 10.3305/nh.2013.28.6.6831
Palabras clave: Lactobacillus paracasei subespecie F19.
Bacterias acidolácticas. Probióticos.
Abstract
Introduction: Many reports in literature have under-
lined particular features of Lactobacillus paracasei subsp
paracasei F19, however a critical review of main clinical
outcomes has not been performed so far. 
Objectives: This review summarizes the most relevant
reports, in terms of clinical benefits, of Lactobacillus
paracasei subsp paracasei F19 administration reviewing
it’s historical background and outlining new interesting
perspectives in clinical practice.
Methods: We searched Pubmed/Medline using the
terms “ Lactobacillus paracasei subsp paracasei F19”. All
clinical and experimental articles on the use of Lactobaci-
llus paracasei subsp paracasei F19 were included. 
Results and discussion: The genetic stability of F19, the
most relevant clinical claim, renders it’s administration
reliable and effective in immunocompromised people.
Adequate concentrations of this strain support a
dose/effect strategy ranging between NF B host macro -
phage activation to pathogenic bacteria overgrowth
control as well as to fine interaction with the gut nerve
endings. Moreover preliminary results from our lab
support the formulation of F19 encapsulated with lyophi-
lized HA in patients with IBD due to both an increased
mucous-strain adherence and a possible enhanced strain
proliferation and maintenance.
Conclusions: Further experiments are required to
overcome the lack of informations about this new formu-
lation for IBD management.
(Nutr Hosp. 2013;28:1842-1850)
DOI: 10.3305/nh.2013.28.6.6831
Key words: Lactobacillus paracasei subsp paracasei F19.
Lactic acid bacteria. Probiotic.
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LAB: lactic acid bacteria.
F19: L. paracasei subsp paracasei F19.
H. pylori: Helicobacter pylori.
P. pentosaceus: Pediococcus pentosaceus.
L. mesenteroides: Leuconostoc mesenteroides.
C. difficile: Clostridium difficile.
B: Bifidobacterium.
EEC: enteroinvasive Escherichia coli.
HA: hyaluronic acid.
E. coli: Escherichia coli.
P. aeruginosa: Pseudomonas aeruginosa. 
Introduction
The Lactobacillus casei (L. casei) group is mainly
composed of lactic acid bacteria (LAB) such as Lacto-
bacillus zeae (L. zeae), L. casei, Lactobacillus para-
casei (L. paracasei) and Lactobacillus rhamnosus (L.
rhamnosus) widely used in dairy products and lactic
beverages and whose major end product of sugar
fermentation is lactic acid. These bacteria are also
gram-positive, nonsporing, catalase-negative ,devoid
of cytochromes and of nonaerobic habit but are aerotol-
erant, unpleasant, acid-tolerant and strictly fermenta-
tive1. Studies on the electrostatic cell surface properties
revealed a pH-dependent configuration with elec-
trophoretic mobility progressively decreasing for
lower pH values for the Lactobacillus casei subsp.
casei (L. casei subsp. casei) and Lactobacillus para-
casei subsp. paracasei (L. paracasei subsp. paracasei)
strains until the isoelectric point (IEP = 4). The pH
variations might be linked to cell wall chemical
composition with adhesion mechanism during gastric
transit2.
The taxonomic position and nomenclature of the L.
casei group has been long time debated3. In the past L.
casei group had been one species divided into five
subspecies: the L. casei subspecies casei, alactosus,
pseudoplantarum, tolerans and rhamnosus4, but in 1989
Collins et al. introduced a reclassification by introducing
two new species: L. paracasei and L. rhamnosus and
tranferring subspecies L. casei subspecies casei to the
species L. casei without any subspecies5. L. paracasei
comprised two subspecies: the subspecies Lactobacillus
including L. casei subspecies alactosus and pseudoplan-
tarum and the subspecies tolerans from the L. casei
subspecies with the same name. 
L. paracasei subsp paracasei F19 (F19) belongs to
the homofermentative family of lactic acid bacteria
which convert almost quantitatively glucose to lactic
acid6. It showed the ability to bind gastric and bovine
mucin, collagen I and III and fibronectin and to express
high surface hydrophobicity. The survival to pH 2.5 for
1 h and 20% bile for 2 h exposure, the bacteriocin(s)
production, the proteolytic activity as well as the ability
the ability to transcribe NF B to the nucleus of
macrophages have made this lactobacillus a reason-
able candidate for a probiotic product development7.
State of the art
F19 was isolated, for the first time, from the deep
colonic mucus layer of patients without gastroin-
testinal disease who were admitted to the Sabbatsberg
Hospital of Stockholm in 20027. Then it was included
in the multicentre European project PROBDEMO,
which involved volunteers from Finland and Sweden,
where its gastric survival ability was assessed and
where strains closely related to F19 were observed in
the intestinal tract of a small percentage of volunteers8. 
Within the PROBDEMO project human pilot
studies, based on the F19 strain, have been conducted.
One involved 61 healthy swedish infants and 30 elderly
that were randomly assigned to receive or gelatin
capsules containing 1×1010 CFU of F19 in corn starch
or corn starch only for 12 weeks9. Fecal samples from
infants treatment group (n = 30), collected before,
during (at 2-3 weeks) and 2 weeks after administration,
revealed an increase of F19 in 6/30 and a reduction of
17% of Clostridium difficile (C. difficile) population.
However the elderly treatment group (n = 13) did not
evidence substantial changes in terms of both micro-
bial colonization and, as for the infants, Helicobacter
pylori (H. pylori) eradication. The overall results indi-
cated the ability of F19 to survive through the gastroin-
testinal tract and in 8-20% to be enclosed in the micro-
biota for several weeks as a part of the normal
microflora. Another trial, still based on the assessment
of gastric survival and mucosal adhesion of F19, indi-
cated that it was both in the lumen and adhered to the
mucosa of the colon (0.9×104 CFU) following 12 day
consumption in 5 individuals10. Potential side-effects of
probiotic consumption, such as intestinal discomfort,
increased flatulence and changes in stool consistency
and frequency, were monitored. All studies reported no
adverse effects. 
A questionable issue that has been extensively
studied for the F19 is the genetic stability assessment,
especially in order to guarantee consumers of the
quality of probiotic11-12. The stability of three extrachro-
mosomal elements (plasmids) within F19 was care-
fully checked in each step of the industrial reproduc-
tion process and their genetic profile was compared
with those determined in the same strain 6 years earlier.
At the end of the study no selection of cured derivatives
was detected and all plasmids resulted unaltered. 
A limited effect of F19 on resistant isolates during
treatment with penicillin and quinolones was also
observed13. In particular, 20 patients (divided in 2
groups) treated with either penicillin or ciprofloxacin
(or norfloxacin) were randomized to receive a placebo
or a probiotic product made of powdered milk (10 g)
and freeze-dried F19 (1010 CFU/ml). Fecal samples,
11. LACTOBACILLUS_01. Interacción  05/12/13  12:06  Página 1843
collected before treatment on day 10 and 1 month after
the start of the treatment, revealed that resistance in
enterococci was not affected by penicillin administra-
tion while quinolone resistance increased during
quinolone treatment. Moreover F19 was recovered in
three samples from 10 patients in penicillin-treated
group (2.1 × 103-5.3 × 104 CFU) and in three samples of
eight patients (2.1 × 103-1.6 × 105 CFU) of the
quinolone-treated group on day 10. Further, one patient
of the quinolone-treated group still harboured the
probiotic strain on day 30 (2.1 × 102 CFU).
The effectiveness of the contemporary oral adminis-
tration of F19 (Genefilus F19, Siffra Farmaceutici,
Florence, Italy) in association with vaginal supposito-
ries containing L. acidophilus has been was tested by
Delia et al14. 60 healthy women (18-40 years) with
suspect or confirmed diagnosis of bacterial vaginosis
were randomized to receive either vaginal supposito-
ries containing Lactobacillus acidophilus (L.
acidophilus) (Calagin, Siffra Farmaceutici, Florence,
Italy) or the same vaginal suppositories plus oral
administration of Genefilus F19 (12.5 × 109 CFU per
sacket). The patients were examined at the end of
therapy (3 months) and 3 months after the end of treat-
ment. A significant reduction of vaginal pH, an
improvement of sniff test as well as of the subjective
symptomatology were observed in both groups at end
of therapy and still decreased during the 3 months
follow-up. However the Genefilus F19-treated group
had a meaningful reduction of vaginal pH and of sniff
test at the end of therapy and a maintenance of positive
effect also after 3 months.
Also the host immunomodulation, a claim of many
probiotics involved in normal immune function devel-
opment, has been analyzed. Based on previous clinical
studies15-18, a synbiotic combination of 1011 CFU of
Pediococcus pentosaceus (P. pentosaceus) 5-33:3,
Leuconostoc mesenteroides (L. mesenteroides) 32-
77:1, F19; L. plantarum 2,362 plus inulin, oat bran,
pectin, and resistant starch (Synbiotic 2000 Forte,
Medipharm, Sweden)19-21, was randomly administered
for 15 days (1 sachet of 12 g) whereas the placebo
consisted of an identical dose of maltodextrin
(Caloreen, Nestle, UK) on 65 critically ill patients21.
Analysis of infections, systemic inflammatory
response syndrome, severe sepsis, and mortality, were
performed. Results indicated that synbiotic-treated
patients significantly reduced the rate of infections (P =
0.01), systemic inflammatory response syndrome,
severe sepsis (P = 0.02), and mortality; further, hospi-
talization within the intensive care unit (P = 0.01) and
days under mechanical ventilation were significantly
reduced with respect to placebo (P = 0.001).
The role of F19 in this mix has been peculiar, it was
the strongest inducer of Th1 and repressor of Th2
cytokines22 and, along with Lactobacillus plantarum
(L. plantarum), was effective to eliminate C. difficile
strains23. On the other hand it is worth noting that the
PRONUT study evidenced that Synbiotic 2000 Forte
did not improve severe acute malnutrition outcomes in
399 Malawian children24. 
On the basis of microbiological evidence it has been
also observed that F19 did not modify CD4 T-cells
growth, responsible for normal immunomediated
response, on the contrary this population was stimu-
lated by L. paracasei subsp. paracasei B2106025.
By means of the gene array technology it has been
possible to map the host global gene expression profile
changes caused by both F19 and L. acidophilus NCFB
1748 administration (5 ×108 CFU/ml)26. Differences in
gene transcription were evaluated in the distal ileum of
normal microflora and germ-free mice. In the normal
microflora mice both strains caused concerted
enhancement in a cluster of genes involved in immune
response (such as Igh-5; Ms4a1; Clu; Cxcl13), some
belonging to B cell receptor-signalling (Cd79a, Ms4a1,
Cd19, Blk, Cd79b, Ptprc), some implicated in phago-
cytosis (Mfge8, Coro1a), in complement function (C3,
Clu), in the architectural organization of B cells within
lymphoid structures (Ltb, Cxcl13) and some impli-
cated in protection against mucosal damage in inflam-
matory bowel disease (Serpina1) suggesting also a
possible role of Lactobacilli in reducing the severity of
inflammatory bowel disease. Although no qualitative
differences on the expression profile of immune
response-related genes were detected the mean signal
increase was higher in mice fed with L. acidophilus
NCFB 1748. In mice raised under germ-free conditions
immune stimulatory effects were not observed obvi-
ously due to gut lymphoid tissue incompetence. More-
over, in germ-free mices fed with Lactobacilli an
increased signal for adiponectin and adipsin (or factor
D)27 in combination with reduced expression of resistin
like βwas observed. 
West and coworkers determined the impact of F19
during weaning on infections and IgG antibody
responses to routine vaccines in 179 infants28. 89
infants were fed cereals with F19 (treatment group)
whereas 90 without F19 (placebo) from 4 to 13 months
of age. All of them were immunized with diphtheria
and tetanus toxoid and a cellular pertussis, polio and
Hib-conjugate vaccines at 5½ and 12 months of age
and the number of days with infections, antibiotic
prescriptions and antibody concentrations to all
vaccines before and after the second and third doses
were assessed. Both groups did not differ in the days
number with infectious symptoms but in days with
antibiotic prescriptions (fewer in the treatment group p
= 0.044); moreover F19 feeding (1 × 108 CFU/ml)
enhanced anti-diphteria concentrations when adjusting
for breastfeeding duration and colonization (p =
0.024). An interaction of the intervention and coloniza-
tion with F19 on anti-tetanus toxoid concentrations
occurred during the course of vaccination (p = 0.035).
No effect exerted by F19 was observed on anti-HibPS
(Polio + Hib) concentrations on infants breastfed <, >
or = 6 months. Nevertheless F19 feeding increased the
capacity to raise immune responses to protein antigens
1844 Alessandro Di Cerbo and Beniamino PalmieriNutr Hosp. 2013;28(6):1842-1850
11. LACTOBACILLUS_01. Interacción  05/12/13  12:06  Página 1844
especially in infants breastfed < 6 months but did not
prevent infections.
One year later the same group evaluated the effects
of F19 feeding on the incidence of eczema and
Th1/Th2 balance during weaning29. From 4 to 13
months of age 89 infants were fed cereals with F19 (1 ×
108 CFU) whereas 90 were only fed cereals. As a proxy
for immune balance it was used the IFN- /IL4 mRNA
expression levels in polyclonally stimulated peripheral
blood T cells. The cumulative incidence of eczema at
13 months was 11% and 22% in the probiotic and
placebo groups, respectively (p < 0.05) and the IFN-γ
/IL4 mRNA ratio was higher in the probiotic compared
with the placebo group (p < 0.05). Conversely, no
differences between groups in serum concentrations of
total or specific IgE were observed. 
F19 has been confirmed to be efficacious and well
tolerated in patients with IBS presenting with diarrhoea
or with constipation30. In particular, 100 IBS patients
both with diarrhoea (n = 52) and constipation (n = 48)
were administered Genefilus F19 at a dose of one
sachet (12 × l09 of F19, combined with 750 mg gluco-
oligosaccharides plus vitamins Bl, B5 and B6),
dissolved in water, twice daily for 14 days. Moreover
the content of F19 was evaluated in the stool of 20
patients before and after treatment. 2 weeks after the
end of the treatment 94% of patients with IBS with
diarrhoea had no more abdominal pain and 88% had no
more diarrhoea; on the other hand, abdominal pain and
constipation were no longer present in 87% and 83% of
patients with IBS with constipation respectively; 95%
of the overall population considerably improved or
eliminated abdominal distension. Microbiological
evaluations of patients stool revealed a marked
increase of F19 load following the treatment, with a
minimum of 2, to a maximum of 10, CFU/g faeces. The
same trend, although with less evidence, was observed
by Simrén et al (2009). 74 IBS patients were random-
ized to receive a daily treatment with either milk
fermented with the yoghurt bacteria and containing
F19, L. acidophilus La5 and Bifidobacterium lactis (B.
lactis) Bb12, 5 × 107 CFU/ml, (n = 37; Cultura; active)
or simply acidified milk without these bacteria (n = 37;
control) for 8 weeks 31. Responders were 14/37 (38%)
patients in the treatment group and 10/37 (27%)
patients in the control group (P = 0.3). IBS symptom
severity improved significantly Both groups had an
improvement of IBS symptom severity during the
treatment period, in particular during the first 2 weeks. 
Based on the evidence that part of the pathogenesis
in chronic fatigue syndrome of the host might be due to
Disturbances in intestinal microbial ecology and in the
immune system32-34 Sullivan et al. (2009) evaluated the
effect of F19, L. acidophilus NCFB 1748 and B. lactis
Bb12, 108 CFU/ml, (Cultura Dofilus Natural Yogurt,
Arla Foods, Stockholm, Sweden) on fatigue and phys-
ical activity in 15 chronic fatigue syndrome (CFS)
patients35. The rationale was that lactic acid producing
bacteria have been shown to prevent and alleviate
gastrointestinal disturbances36 and to normalize the
cytokine production37 and that such regulatory mecha-
nism may be useful for CFS suffering patients. After 4
week of probiotic intake neurocognitive functions
were improved in 6/15 patients, while no significant
changes in fatigue and physical activity scores as well
as in the gastrointestinal microflora were observed.
It has been observed that gut microbiota modulation,
by means of probiotics intake, could be used also
during obesity intervention strategies38-39.
In particular, F19 supplementation, was shown to
increase the levels of lipoprotein lipase inhibitor
ANGPTL4 (involved in the triglyceride deposition
control into adipocytes) and peroxisome proliferator
activated receptors (PPARγ and PPARα) specific
targets for the treatment of type 2 diabetes and dyslipi-
daemia40. ANGPTL4 inhibited lipoprotein lipase action
decreasing fat storage41. To investigate the effects of
F19 supplementation SPF C57B/6J mice were used
due to their propensity for weight gain. After 10 week
treatment the serum analysis revealed that free fatty
acids were not affected by the presence of F19, while
the triglyceride load of the lipoprotein VLDL showed a
slight but significant increase although cholesterol
levels remained unchanged; on the other hand circu-
lating ANGPTL4 levels were up-regulated and
magnetic resonance imaging showed a significantly
reduced body fat profile.
Recently, Nardone et al. (2010) have proposed the
use of F19 as protective agent in a rat model with
induced oxidative and metabolic hepatic injury (30 min
ischemia and 60 min reperfusion)42. More in detail, 27
Wistar rats were fed a standard diet and 27 rats a
methionine/choline deficient diet for 8 weeks before
the ischemia/reperfusion procedure; within each group
7 rats were sham-operated to determine baseline condi-
tions, 10 rats underwent I/R of the liver whereas 10 rats
underwent I/R after dietary supplementation with F19
(3 × 107 CFU) for 8 weeks. After I/R rats fed a standard
diet showed a decrease in sinusoid perfusion (P <
0.001), a severe liver inflammation, necrosis, an
increase of tissue levels of MDA (P < 0.001), TNF-α (P
< 0.001), IL-1 (P < 0.001), IL-6 (P < 0.001) as well as
of serum levels of transaminase (P < 0.001) and LPS (P
< 0.001) with respect to sham-operated rats. A decrease
in Bacterioides, Bifidobacterium, and Lactobacillus
spp (P < 0.01, P < 0.001, and P < 0.001, respectively)
and an increase in Enterococcus and Enterobacteri-
aceae (P < 0.01 and P < 0.001, respectively) on
intestinal mucosa was also observed. F19 supplemen-
tation significantly reduced the harmful effects of I/R
on the liver and on gut microbiota in both groups of
rats, however in methionine/choline deficient-fed rats,
where the severity of liver and gut microbiota alter-
ations were greater, a slightly less effect was observed. 
Annibale et al. (2011) have successfully proposed
the use of Genefilus F19 along with a high-fibre diet,
for abdominal bloating and prolonged abdominal pain
reduction in symptomatic uncomplicated diverticular
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disease43. 50 Patients were randomized to receive a
high-fibre diet; 1 sachet of probiotic plus (12 × 109
CFU) a high-fibre diet (twice daily); 2 sachets of probi-
otic + high-fibre diet (twice daily) for 14 days/month
for 6 months. Both probiotic-treated groups had a
significant decrease in bloating [VAS score were 4.6 ±
2.6 (baseline) vs. 2.3 ± 2.0 (end of treatment), P < 0.05
and 3.9 ± 2.9 vs. 1.8 ± 2.1, P < 0.05 respectively for the
two groups] but not a significant decrease in abdominal
pain within 24 hours and < 24 hours. Notably, 7
patients belonging to the probiotic-treated groups with
abdominal pain > 24 hours did not report the recurrence
of this symptom whereas 3 patients of the high-fibre
diet- treated group reported at least one episode (P =
0.016). 
A recent study has highlighted the potential use of
F19 in NEC Bell’s stage 2 (the most common acquired
acute gastrointestinal illness in the neonatal period that
affects about 5% of infants with birthweight ≤1,500 g
and that is characterized by abdominal distension,
bloody stools and pneumatosis intestinalis) in order to
prevent the clinical progression to stage 344. 32 infants
with birth weight 600 to 1500 g were randomly
assigned to receive either a 5 ml probiotic supplemen-
tation (n = 18; F19; 6 × 109 CFU/day for 21 days) or
standard medical treatment (n = 14). F19 supplementa-
tion was associated with lower progression to stage 3
(P < 0.05), lower mortality rate and shorter hospital
stay (P < 0.05). Moreover none of probiotic-treated
patients presented either sepsis or intestinal complica-
tions such as diarrhea.
The hypothesis that enteric glial cells might partici-
pate in host–bacteria cross-talk has been evaluated by
Turco et al. (2013)45. Primary cultures of human enteric
glial cells have been exposed both to live and heat-killed
pathogenic enteroinvasive Escherichia coli (EEC) and
probiotic (F19; 3.4 × 108 CFU/ml) bacteria. Results indi-
cated that EEC activated enteric glial cells inducing the
cFos and MHC II expression. After 6h exposure TLR1,
TLR3 and TLR4 mRNA expression was significantly
up-regulated by both EEC and F-19 (p < 0.01) with
respect to the basal level. On the other hand, EEC
induced a higher TLR3 expression (p < 0.01) and a
significantly lower expression of TLR5 and TLR7 (p <
0.01) with respect to F19. After 24 hours exposure
TLR7, TLR9 and TLR5 mRNA expression was signifi-
cantly up-regulated only by F19 (p < 0.01) with respect
to the basal level. Moreover TLR2 expression was
significantly up-regulated by both EEC and F19 (p <
0.01) with respect to the basal level, however TLR3
expression was significantly up-regulated only by EEC
(p < 0.01) and conversely TLR7, TLR9 and TLR5
mRNA expression was significantly up-regulated only
by F19 (p < 0.01) with respect to the basal level.
Notably, EEC induced a significantly higher expression
of TLR2, TLR3, TLR7 and TLR9 (p < 0.01) and a lower
TLR5 expression (p < 0.01) with respect to F19.
When enteric glial cells were challenged for 6 h with
either heat-inactivated EEC or F19, TLR2, TLR7 and
TLR9 expression was virtually undetectable with
respect to the basal level while TLR5 expression was
significantly down-regulated by heat-inactivated EEC
(p < 0.01). After 24 h challenge, heat-inactivated EEC
significantly up-regulated TLR3 expression (p < 0.01)
with respect to the basal level whereas both heat-inacti-
vated EEC and F19 up-regulated TLR4 expression (p <
0.01). The analysis of differences between viable and
heat-inactivated EEC and F-19 revealed that after 6 h,
but not 24 h, challenge TLR expression induced by
viable organisms was significantly different from heat-
inactivated ones.
Interestingly, immunofluorescence analysis showed
that TLR2 was mainly detected in the cytoplasm and in
the plasma membrane of enteric glial cells while TLR3
and TLR4 were mainly cytosolic and nuclear. More-
over, western blot analysis of enteric glial cells showed
that EEC, but not F19, induced nuclear translocation of
NF Bp50 protein (p < 0.05) with respect to the basal
level as well as TLR2, TLR3 and TLR4 agonists (p <
0.05). Conversely, when enteric glial cells were treated
with the specific MyD88-blocking peptide, only the
TLR3 agonist significantly increased NFκBp50
expression (p < 0.05) with respect to the basal level
while TLR2 and TLR4 agonists failed to induce
NFκBp50 nuclear translocation. Finally, after 24 h
exposure to both viable EEC and F19, S100B protein
expression (and consequently NO release) was signifi-
cantly higher in response to the first one (p < 0.01)
compared to basal conditions. This study emphasizes
both the aspect that enteric glial cells express TLR
(involved in the innate immune system response mech-
anism)38 and their role in discriminating between
pathogens and probiotics by modulating TLR expres-
sion. More recently Palumbo et al. (personal comuni-
cation) have further characterized the enteric glial cells
- F19 interaction evaluating the effects of mediators
released by these cells after probiotic challenge by
means of conditioned media analysis46. In particular,
conditioned media from probiotic stimulated cells
showed increased lactase activity as compared to the
untreated ones (1.15 ± 0.17 and 1.29 ± 0.19 fold
increase vs control p < 0.05). However, a decreased
lactase activity was observed when enteric glial cells
were treated with pathogens (0.85 ± 0.23 fold decrease
vs control p < 0.05).
F19: in vitro study of a potential new prebiotic
enhancing activity 
The concept of a possible combined administration of
F19 with some new prebiotic enhancer, induced our
research group to focus on the lactobacilli interaction
with hyaluronic acid (HA), a large linear glycosamino-
glycan which is mostly present within extracellular
matrix47, that in previous microbiological and virological
investigations had shown some definite properties in
controlling the pathogenic bacteria and viruses growth48.
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The role of HA on in vitro growth rate of F19 was inves-
tigated by means of an innovative technique. The proce-
dure consisted in introducing, in 10 sterile vials already
filled with an eugonic broth, 106-7 CFU/ml of F19 plus a
decreasing concentration of HA (from 1 to 0.125 mg ml-1)
and placing these in a bacterial culture (HB&L™;
Alifax, Padova, Italy). HB&L™ was used for the real
time detection of bacteria growth curves. such analyzer
is a new combination of a turbidimeter (based on the
dynamic light scattering mechanism), with Mc Farland
Monitor and an incubator within the same device and,
for the first time, successfully used to accelerate studies
on lactobacillus strain growth investigations. Each
sample is analyzed by two laser beams which have their
own photodetector, one more sensible (placed at 30°
with respect to the beam source) and one more specific
(placed at 90° with respect to the beam source).
With this investigation diagnostic device we demon-
strated that HA concentration, from 1 to 0.125 mg ml-1,
resulted in an increased bacterial strains growth within
24 hours (fig. 1). Observations might suggest a
possible protective role of low doses of HA towards
F19, supporting its in vivo proliferation and engraft-
ment after oral administration. 
Although speculative, a possible role of HA on the
bacterial growth and proliferation might be ascribed to
the ability of some strains of utilizing HA as a carbon
source. 
Discussion
The issue of a single lactobacillus administration
compared with a pool in the probiotic therapy scenario
has been debated long time without a definite indica-
tion: the concept that links each single microbiologic
agent to a well defined biochemical or genetic interac-
tion within the host environment is a clear cut premise
to achieve the goal of an effective medical treatment
with some sort of pharmacological approach in micro-
biology.
Very often the production and market of a mixed
lactobacilli combination in nutraceutical products did
not previously take into account the in vitro interaction
between each other strain, and the impact of a stranger
microbiological task force intrusion into the gut envi-
ronment, doesn’t guarantee at all a quicker integration
or a better balance of different pathogenic versus
saprophytic populations.
The bioavailability of a single strain formulation,
like in the case of F19 in adequate concentration,
supports a dose/effect strategy ranging between NFκB
Fig. 1.—Effects of HA on F19 until 24 hours. The strain was employed at a starting concentration of 1 × 106-7 CFU/ml. In presence of
MRS only (first two windows) F19 mean growth was quite inhibited; however in presence of MRS + HA [1 mg/ml] (3rd and 4th window),
MRS + HA [0.5 mg/ml] (TH AND 6H WINDOW); MRS + HA [0.25 mg/ml] (7th and 8th window); MRS + HA [0.125 mg/ml] (9th and 10th
window) a mean bacterial growth enhancement was observed with respect to control (F19 alone).
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macrophage activation plus immunity host modula-
tion, and the success over pathogenic bacteria over-
growth moreover the F19 fine interaction with the gut
nerve endings, as it has been demonstrated by the in
vitro experiment of Turco et al. achieves convincing
explanation of the clinical healthy effect on IBD symp-
toms during nutraceutical treatment with this lacto-
bacillus. Other experimental investigations opened the
hypothesis that F19 displays some metabolic activating
properties in the lipid imbalance and in the liver
impaired functions.
Last, but not least, the genetic stability of the strain is
a first class safety clinical claim, especially when
probiotic therapy is required in very weak, immuno-
compromised people, with altered mucous barrier and
with the real risk of lymphohematogenous spread of
the bacteria into the bloodstream. 
The term bacterial translocation, coined by Berg and
Garlington49, has been defined as the passage of both
viable and non-viable microbes and microbial products
(endotoxins) from the intestinal lumen through the
epithelial mucosa into the mesenteric lymph nodes and
then to other organs. It might be related to a decrease in
microbes turnover rather than an increase in their
transepithelial penetration and those which seem to
translocate most readily hold the ability to both survive
in the bloodstream and to resist leucocyte digestion and
phagocytic killing (e.g. Salmonella species). On the
contrary, normal enteric species are easily killed after
phagocytosis (whit the only exception of Escherichia
coli (E. coli), other enterobacteriaceae, Pseudomonas
aeruginosa (P. aeruginosa), enterococci and some
streptococci50, surviving only under circumstances in
which host defences are impaired. Recent findings have
ascribed the ability of translocate of these specific
strains to a better adherence and facilitated attachment
to the mucus-epithelium layer with respect to nonpatho-
genic strains51. Although intestinal anaerobic bacteria
(such as Lactobacilli) exceed aerobic bacteria by 100:1
to 1000:1 and act as an insulating layer over the mucous
on the mucosal surface, limiting colonization and over-
growth of other potentially invasive microbes52, their
translocation has been reported only in extreme circum-
stances such as athymic53, lethally irradiated54 or
severely burned rodents50 and in all these conditions
there are breaks in enteric integrity and the bacterial
translocation appears to be in direct proportion to the
degree of tissue damage. The fact that the aerobic
Gram-negative bacilli can translocate even across histo-
logically intact intestinal epithelium52 (through morpho-
logically intact enterocytes55) and that selective elimina-
tion of anaerobic bacteria facilitates intestinal
accumulation and translocation of facultative bacteria,
has led to the assumption that bacterial overgrowth
might be one of the main factors (reduced gastric
acidity56, impaired gastrointestinal motility and, conse-
quently, prolonged intestinal transit time57 promoting
bacterial translocation. However bacterial translocation
can occur in the normal host, shown by recovery of
viable intestinal bacteria from mesenteric lymph nodes
in a small proportion of healthy animals and humans58-59
and is a probably normal and essential process, regu-
lating local and systemic immunity and tolerance to the
innumerable antigens that make contact with the
intestinal epithelium60. Usually, enteric bacteria translo-
cation by oral antibiotics displacement remains
confined to the satellite mesenteric lymph nodes and do
not appear to extend a persistent infection state, more-
over when the antibiotic is discontinued the caecal
population of enteric organisms returns to normal
levels61-62. In this context, however, immunosuppression
can activate the translocating bacteria to spread system-
ically, ultimately resulting in lethal sepsis63. Moreover,
the lower part of the gut, which contains a large number
of microbes, has been suggested to hold a more efficient
capacity for killing translocated bacteria with respect to
the upper part; in particular the colon, which has been
demonstrated to have higher electrical resistance and
lower permeability to the passive movement of ions64.
The lactobacilli translocation is a not uncommon rele-
vant event that might rise pathogenic complications and
even septic death: the genetic stability of F19,
confirmed in more than 20 years of clinical use, not only
is reassuring that the up date risk of spontaneous muta-
tion is not consistent, but even in case of hematogenous
spread of F19, it will maintain its proper immunomodu-
lating activity; thus rendering the invaded host more
active in the cell-mediated defence against the septic
agents, but also it can be easily destroyed by the stan-
dard antibiotic dosages, being it’s antibiogram still
unchanged since 20 years.
A final comment about the F19 high daily concentra-
tion during the oral intake: being F19 acid-bile resistant
it’s transit through the proximal gastrointestnal tract
leaves a great number of lactobacilli viable for the
colonic harboring and able to survive in the colonic
environment for at least three months after 4 weeks of
oral intake. This means a prolonged therapeutic effect
and a better temporary integration in the host micro-
biota related to the length of F19 administration with
the confidence that the high lactobacilli count pro dose
is without untoward effects (bloating, constipation or
other common symptoms observed during probiotic
administration, were not detected during F19 oral
intake inducing an excellent compliance by the users.
Summarizing, based on recent achievements, F19,
provided of genetical stability, actively interacts with
gut epithelium and immune system, correlating with
both gene sequences and genes whose down-regulation
may be the cause of gastrointestinal pathologies. 
Our present preclinical investigation addresses us to
perform a next pilot study to administer F19 encapsu-
lated with lyophilized HA in patients with IBD, in
comparison with the existing formulation, in order to
evaluate further symptomatic benefits due to the gut
mucosa-lactobacillus interaction with a better mucous-
germ adherence, and possible enhanced F19 prolifera-
tion and bioavailability into the gut lumen.
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As matter of fact, an other our previous unpublished
study on the HA administration by enemas on a group
of patients with ulcerative colitis under Pentasa treat-
ment showed a remarkable symptomatic benefit on the
number of stool-mucous discharges, bloating and pain.
We have thus a rationale to suppose that further
benefit will be achieved by the synergy between probi-
otic and glycosaminoglycan administration. Further-
more F19 as a single therapeutic agent we’ll more
easily identify further specific benefits not only in the
bowel inflammatory and motion control, but also in
other indications related to it’s metabolism in the
commensal environment such as obesity and steatosis,
during glyco-lipidic imbalance of diabetes, potential
treatment. 
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